Sign inCreate account

Report workspace

Add to folder
NCT05999916COMPLETEDanonymous

A Prospective, Single-Arm, Monocentric Pilot Study to Evaluate the Safety and Feasibility of Transcranial Alternate Current Stimulation With the Miamind Neurostimulator in Healthy Participants

Sponsor

Source record

Bottneuro AG

Phase

Source record

Pilot Study (Not classified under traditional phases)

Modality

AI-normalized

medical device

Target

AI-normalized

Transcranial alternating current stimulation (tACS) targeting brain oscillations, specifically at gamma frequency (40 Hz), to enhance cognitive functions and potentially treat Alzheimer's Disease.

Indication / condition

AI-normalized

Healthy Participants

Intervention

Source record

Personalized Miamind Neurostimulator

Source & freshness

Source record

NCT ID

NCT05999916

Original source

ClinicalTrials.gov

Source last updated

Aug 06, 2024

Ingested at

Jun 16, 2026

Internal sync

Jun 16, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05999916

Title

A Prospective, Single-Arm, Monocentric Pilot Study to Evaluate the Safety and Feasibility of Transcranial Alternate Current Stimulation With the Miamind Neurostimulator in Healthy Participants

Sponsor

Bottneuro AG

Status

COMPLETED

Phase

Pilot Study (Not classified under traditional phases)

Condition raw

Healthy Participants, Healthy Population

Condition normalized

Healthy Participants, Healthy Population

Modality raw

medical device

Modality normalized

medical device

Target raw

Transcranial alternating current stimulation (tACS) targeting brain oscillations, specifically at gamma frequency (40 Hz), to enhance cognitive functions and potentially treat Alzheimer's Disease.

Target normalized

Transcranial alternating current stimulation (tACS) targeting brain oscillations, specifically at gamma frequency (40 Hz), to enhance cognitive functions and potentially treat Alzheimer's Disease.

Interventions

Personalized Miamind Neurostimulator

Public preview

Source record

Bottneuro AG's Miamind Neurostimulator is positioned in the emerging field of non-invasive brain stimulation technologies, targeting cognitive enhancement and Alzheimer's Disease treatment. The pilot study's completion indicates a step towards larger trials, which could attract interest from investors and partners in the neurotherapeutics market. The global Alzheimer's Disease therapeutics market is projected to grow significantly, driven by increasing prevalence and demand for innovative treatment options. The success of this pilot could provide Bottneuro with a competitive edge, particularly if future studies demonstrate efficacy in cognitive improvement. However, the competitive landscape includes established players in neurostimulation and cognitive enhancement, necessitating a robust strategy for differentiation and market entry.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Prospective, Single-Arm, Monocentric Pilot Study to Evaluate the Safety and Feasibility of Transcranial Alternate Current Stimulation With the Miamind Neurostimulator in Healthy Participants

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT05999916

Status

COMPLETED

Phase

Pilot Study (Not classified under traditional phases)

Sponsor

Bottneuro AG

Executive brief

Investment-Ready Snapshot

Bottneuro AG's Miamind Neurostimulator is positioned in the emerging field of non-invasive brain stimulation technologies, targeting cognitive enhancement and Alzheimer's Disease treatment. The pilot study's completion indicates a step towards larger trials, which could attract interest from investors and partners in the neurotherapeutics market. The global Alzheimer's Disease therapeutics market is projected to grow significantly, driven by increasing prevalence and demand for innovative treatment options. The success of this pilot could provide Bottneuro with a competitive edge, particularly if future studies demonstrate efficacy in cognitive improvement. However, the competitive landscape includes established players in neurostimulation and cognitive enhancement, necessitating a robust strategy for differentiation and market entry.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 06, 2024
Internal syncJun 16, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05999916

Indication

Healthy Participants

Modality

medical device

Target

Transcranial alternating current stimulation (tACS) targeting brain oscillations, specifically at gamma frequency (40 Hz), to enhance cognitive functions and potentially treat Alzheimer's Disease.

Intervention

Personalized Miamind Neurostimulator

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.